TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04035889

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT01070979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol acetate
Description: Tablet containing 0.9 mg E3A, daily oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol
Description: Tablet containing 1 mg estradiol, daily oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conjugated equine estrogens
Description: Tablet containing 0.625 mg CEE, daily oral administration.
Study: NCT02271061

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio tape
Description: Elastic therapeutic tape is one type of elastic tape that is widely used for various treatment including rehabilitation and sports injuries . The elastic therapeutic tape has different characteristics from other kind of tape. It has ability to stretch around 130 - 140% from original length and recoil back to starting length after applying the tape. Tape produces pulling force on skin which lifts and folds layers of epidermis . Pulling force provides an appropriate alignment which can facilitate and inhibit muscle contraction.It has been claimed for several benefits such as supportingly injured muscles, increased proprioception, stimulated and inhibited muscle activity, relieved pain, increased range of motion, and improved blood and lymph flow.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control tape
Description: Apply tape in same technique without tension.
Study: NCT01830985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-509
Description: VX-509 dose may be increased every 8 weeks in a stepwise fashion from 100 to 150 mg and from 150 to 200 mg, as needed (determined by ongoing disease activity by CDAI)
Study: NCT01265017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol, medroxyprogesterone, hydrocortisone, GH
Description: * Estradiol 1mg every 8 hours administered orally~* Medroxyprogesterone 2.5 mg every 24 hours administered orally~* Hydrocortisone 2.5 mg every morning, 1.25 mg every afternoon, and 1.25 mg at bedtime administered orally~* Growth hormone 2 mg once a day administered by subcutaneous injection,

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: matching placebo
Study: NCT01952938

Intervention type: PROCEDURE
Intervention: LINK SL versus EnduRo

Intervention type: PROCEDURE
Intervention: LINK SL versus EnduRo
Study: NCT02252315

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Brochure
Description: Participants will receive written education materials about mild traumatic brain injury.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Verbal education module
Description: A structured in-person education module about mild traumatic brain injury.
Study: NCT03539757

Intervention type: DEVICE
Intervention: Non-Contrast Magnetic Resonance Imaging
Description: The investigators plan to prospectively assess the correlation of liver fibrosis and congestion measurements obtained from novel, non-contrast MR imaging methods to histopathologic data obtained from a clinically-indicated liver biopsy in Fontan patients.
Study: NCT01583673

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amino Acid Formula
Description: Subjects will be fed the assigned study formula from enrollment to 4 months (112 days) of age.Infants will be fed orally, ad libitum with the assigned formula

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Amino Acid formula
Description: Subjects will be fed the assigned study formula from enrollment to 4 months (112 days) of age.Infants will be fed orally, ad libitum with the assigned formula
Study: NCT03886467

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community-based nutrition education
Description: Nutrition education will be included in community development training. The nutrition education will target child nutrition, particularly consumption of animal-source foods and especially milk. The importance of dietary diversity will also be emphasized. Demonstrations of food preparation techniques will also be included in the training.
Study: NCT01293812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 88% sucrose po solution
Description: 88% sucrose solution (Syrup B.P.) The pharmacy will provide 2 syringes labeled sucrose study calculated to provide a 2 ml dose of a 88% sucrose solution or a color, consistency- and odor-matched placebo in identical packagings (2 syringes per patient in the case the dose needs to be repeated).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo po
Description: The pharmacy will provide 2 syringes labeled sucrose study calculated to provide a 2 ml dose of a solution or a color, consistency- and odor-matched placebo to the sucrose solution in identical packagings (2 syringes per patient in the case the dose needs to be repeated).
Study: NCT03361215

Intervention type: OTHER
Intervention: Biosampling for molecular analysis
Description: Observational study with no therapeutic intervention. Biosampling for molecular analysis

Intervention type: OTHER
Intervention: Biosampling for molecular analysis
Description: Observational study with no therapeutic intervention. Biosampling for molecular analysis
Study: NCT01663311

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medial Frontal rTMS Double-Cone-Coil
Description: High frequency rTMS ( Alpine Biomed Mag Pro Option) applied over medial superior frontal cortex (supplementary motor cortex) (Brodman area 6/8),Double-Cone-water-cooled-Coil (2000 Stimuli of 10 Hz each session), 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left DLPFC Butterfly Coil
Description: High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 20 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold.
Study: NCT02708680

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entinostat
Description: An orally available histone deacetylases inhibitor (HDAC).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: A humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death ligand 1 (PD-L1).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atezolizumab
Description: A humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death ligand 1 (PD-L1).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A pill containing no active drug ingredient
Study: NCT01634217

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iTreg
Description: The iTregs will be infused at the assigned dose without a filter or pump slowly by gravity over 15-60 minutes. The iTregs should be given at least 4 hours before the peripheral blood stem cell (PBSC) infusion (MT2001-10).
Study: NCT02935166

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory muscle training
Description: General high-intensity training consists in maximum effort intervals of 30 seconds duration against an equivalent resistance 0.075 kg / kg of body mass followed by a recovery period of 4 minutes cycle ergometer; the total duration was 3 weeks. They were made in this regard, five weekly sessions of 30 minutes per session, Additionally, randomly, the patients were divided into one of 3 possible groups of respiratory training, which consisted of 5 sets of 10 full breaths (inspiration and expiration) in the morning and afternoon during 3 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory muscle training
Description: General high-intensity training consists in maximum effort intervals of 30 seconds duration against an equivalent resistance 0.075 kg / kg of body mass followed by a recovery period of 4 minutes cycle ergometer; the total duration was 3 weeks. They were made in this regard, five weekly sessions of 30 minutes per session, Additionally, randomly, the patients were divided into one of 3 possible groups of respiratory training, which consisted of 5 sets of 10 full breaths (inspiration and expiration) in the morning and afternoon during 3 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Respiratory muscle training
Description: General high-intensity training consists in maximum effort intervals of 30 seconds duration against an equivalent resistance 0.075 kg / kg of body mass followed by a recovery period of 4 minutes cycle ergometer; the total duration was 3 weeks. They were made in this regard, five weekly sessions of 30 minutes per session, Additionally, randomly, the patients were divided into one of 3 possible groups of respiratory training, which consisted of 5 sets of 10 full breaths (inspiration and expiration) in the morning and afternoon during 3 weeks.
Study: NCT00003748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: One course of therapy is comprised of a 4-week treatment period and a two-week rest period. Drug administration will be based on actual calculated body surface area. Starting dose will be 125 mg/m2/day given once per week on four consecutive weeks.
Study: NCT03499418

Intervention type: OTHER
Intervention: modified Silverman scale
Description: Clinical assessment of severity of respiratory failure

Intervention type: OTHER
Intervention: modified Silverman scale
Description: Clinical assessment of severity of respiratory failure

Intervention type: DIAGNOSTIC_TEST
Intervention: echocardiography
Description: echocardiographic evaluation of haemodynamic problems
Study: NCT01649466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAF237
Description: Vildagliptin will be used as commercially available tablets of 50mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Protaphane
Description: Protaphane will be used as commercially available injection pens
Study: NCT04183647

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: whole body vibration / local vibration
Description: Both the whole-body vibration application and the local vibration application will be applied to the patients in our cross-over study. Between the two applications will be given a washout period of one week. Patients will be evaluated both local and whole body vibration applications, 1 minute and 60 minutes after the end of the applications. After the evaluation, the patient will be rested in the sitting position until the evaluation at the 60th minute.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: whole body vibration / local vibration
Description: Both the whole-body vibration application and the local vibration application will be applied to the patients in our cross-over study. Between the two applications will be given a washout period of one week. Patients will be evaluated both local and whole body vibration applications, 1 minute and 60 minutes after the end of the applications. After the evaluation, the patient will be rested in the sitting position until the evaluation at the 60th minute.
Study: NCT03489161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: buprenorphine/naloxone 4mg/1 mg for Clinical Opioid Withdrawal Scale (COWS) scores between 8 and 12, or 8mg/2mg S/L ≥ 12 by the sublingual route
Study: NCT04001920

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training program
Description: 12-week, 18-session training program. To offer a complete training program aimed at improving function it was divided : the first 6 weeks were dedicated to strength-training (2 sets of 6 repetitions at 80% of 1-RM), whereas the following weeks focused on endurance-training (1 set of 25 repetitions at 40% of 1-RM).
Study: NCT04551911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rayaldee
Description: 30 mcg calcifediol Extended-Release (ER) Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mcg calcifediol Extended-Release (ER) Capsule
Study: NCT03801538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa
Description: Peginterferon Alfa-2A 180 micrograms/week or Peginterferon Alfa-2B 180 micrograms/week, for at most 96 weeks.
Study: NCT02304679

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4 weekly LIESWT (Wave 1) with the RENOVA device
Description: Following final inclusion, patients will have weekly LIESWT sessions (one session per week for four weeks). Particular attention is given to the recording of complications/adverse events. At the end of each session, the patient is asked to evaluate the level of pain that occurred during the session using a visual analog scale.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: 4 weekly sham LIESWT (Wave 1) with the RENOVA device
Description: Following final inclusion, patients will have weekly sham LIESWT sessions (one session per week for four weeks). Particular attention is given to the recording of complications/adverse events. At the end of each session, the patient is asked to evaluate the level of pain that occurred during the session using a visual analog scale.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up questionnaires 1 month after Wave 1
Description: (Month 2)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.
Study: NCT03801538

Intervention type: DRUG
Group type: OTHER
Intervention: Nucleoside Analog (Substance)
Description: Patients do not need to change their NAs treatment.
Study: NCT04180553

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Point of Care Ultrasound (POCUS)
Description: The intervention group will receive a 4-view transthoracic echocardiogram including Parasternal long axis, parasternal short axis, apical 4-chamber, and supplemental subcostal short-axis/4-chamber views as needed. A standard 4-view thoracic lung ultrasound study will assess the left and right anterior chest wall, anterior axillary regions, as well as the costophrenic angle and posterolateral regions. At 5 discrete time intervals post-operatively, POCUS assessments will be used to adjust fluid resuscitation to fluid liberal (2cc/kg/hr) or fluid restrictive (0.8cc/kg/hr). Routine vital signs, biochemistry, and urine output as well as bedside physical exam will be assessed as usual. IV boluses of crystalloid will be permitted to treat hypotension with SBP \<90mmHg with clinical signs of hypovolemia, but oliguria will not be used as a marker to titrate fluid infusion rates. Blood transfusion may be used for post-operative bleeding or anemia as clinically indicated.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The control group for usual care will undergo resuscitation guided by modalities used currently, which can include both static and dynamic measures. These will include review of vital signs, biochemistry, and urine output as well as bedside physical exam. In this arm, patients will not undergo POCUS during their admission. IV fluid infusion rates as well as targets for IV boluses will be left to the discretion of the attending physician and can include hypotension, hypovolemia, as well as oliguria. Blood transfusion may be used for post-operative bleeding or anemia as clinically indicated.
Study: NCT00225121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00299804
Description: investigational drug by oral route (escalating doses depending on safety) administered until progression
Study: NCT00569881

Intervention type: DRUG
Intervention: gatifloxacin and moxifloxacin
Description: Comparison of wound healing between drugs
Study: NCT02859948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKLB1028
Description: SKLB1028 capsules in six doses beginning at 20 mg and rising to 200 mg.
Study: NCT01207505

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhancing Emotion Regulation
Description: 12 week of group therapy 3 modules: 1) mindfulness, 2) emotion regulation, 3)distress tolerance
Study: NCT00725530

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A contact lens (PureVision)
Description: Commercially marketed, silicone hydrogel contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A contact lens (PureVision)
Description: Commercially marketed, silicone hydrogel contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A contact lens (Acuvue2)
Description: Commercially marketed, hydrogel contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A contact lens (Acuvue2)
Description: Commercially marketed, hydrogel contact lens
Study: NCT02384941

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily, before first meal of the day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo once daily, before first meal of the day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Sotagliflozin once daily, before first meal of the day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Sotagliflozin once daily, before first meal of the day.
Study: NCT01066949

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral self mangement
Description: Seven weekly, hour long group sessions focused on enhancing patient behavioral self management skills.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support and discussion
Description: Seven, weekly hour long group sessions focused on information provision and supportive discussion amongst participants
Study: NCT00865618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg Tablets Sandoz Inc., USA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inspra 50 mg Tablets GD Searle LLC, USA
Study: NCT02107326

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Webdia Software
Study: NCT00988689

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: soup with or without starch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: soup with or without starch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: soup with or without starch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: soup with or without starch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: soup with or without starch
Study: NCT04154306

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red clover
Description: 2 weeks of Red clover

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 weeks of Placebo
Study: NCT02776579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Girls-only resistance training
Study: NCT01799317

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D2
Description: These patients will receive standard of care vitamin D 1,25 therapy with intervention of vitamin D2
Study: NCT04281979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Study Agent
Description: The study agent will be administered via beverages and/or a capsule. The substances used in the study are legal, non-prescription, and are proven safe for human consumption at the doses used. The study agent may be a depressant (such as alcohol), a stimulant (such as caffeine), or an analgesic (such as aspirin).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the placebo conditions participants will consume beverages and capsules that contain no or very small quantities of the study agent.
Study: NCT03078452

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Power drill
Description: Undergo bone marrow biopsy using power drill

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jamshidi needle
Description: Undergo bone marrow biopsy using Jamshidi needle
Study: NCT00852566

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: Per oral imatinib 400mg once daily (continuous medication)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Per oral dasatinib 100mg once daily (continuous medication)
Study: NCT04125121

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane-propofol
Description: General anaesthesia with a maintenance phase of two hours duration with either sevoflurane or propofol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane-propofol
Description: General anaesthesia with a maintenance phase of two hours duration with either sevoflurane or propofol.
Study: NCT03722095

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active tDCS
Description: A current of 2 milliampère (mA) through electrodes of 5x5cm.
Study: NCT02971254

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Study: NCT03722095

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: Similar set-up as in the active tDCS, but stimulation is too short to cause any effects.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iTBS
Description: 54 cycles with 10 bursts of 3 pulses, train duration of 2 seconds and intertrain intervals of 6 seconds, results in 1620 pulses at 110% resting motor threshold.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: iTBS
Description: 54 cycles with 10 bursts of 3 pulses, train duration of 2 seconds and intertrain intervals of 6 seconds, results in 1620 pulses at 110% resting motor threshold.
Study: NCT00361114

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulphadoxine/pyrimethamine
Description: Sulfadoxine/pyremethamine (SP) given as a single dose per manufacturers recommendation (tablets 500mg sulphadoxine and 15mg pyremethamine; child's body weight 5-10Kgs ½ tablet, 11-20Kgs 1 tablet, 21-30 Kgs 1 ½ tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorproguanil/dapsone
Description: Chlorproguanil/ dapsone (CD) given daily for 3 days per manufacturers recommendations (tablets chlorproguanil 15mg/ dapsone 18.75 mg; 5-7.9Kgs 1 tablet, 8-11.9 Kg 1 ½ tablets, 12-15.9 2 tablets, 16-20.9 Kgs 2 ½ tablets, 21- 40Kg 5 tablets).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine/pyrimethamine
Description: Sulfadoxine/pyremethamine (SP) given as a single dose per manufacturers recommendation (tablets 500mg sulphadoxine and 15mg pyremethamine; child's body weight 5-10Kgs ½ tablet, 11-20Kgs 1 tablet, 21-30 Kgs 1 ½ tablets)
Study: NCT02971254

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane